Sangamo data shows effectiveness of SB-509 in neuropathy

By Lisa Kerner

Charlotte, N.C., Sept. 18 - Sangamo BioSciences, Inc. said clinical data from its ongoing phase 1 studies demonstrate that a single treatment of SB-509 in diabetic neuropathy was well tolerated. No drug-related severe adverse events were observed.

Injection site reactions were the most common adverse events reported. Anecdotal clinical improvements in perception of vibration and improvements in average total neuropathy score were also observed.

The Richmond, Calif.-based pharmaceutical company presented its data at the European Association for the Study of Diabetes in Denmark.

Sangamo plans a phase 2 study later this year of SB-509, a formulation of a zinc finger DNA-binding protein transcription factor.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.